Wednesday, March 28, 2007

MAP Pharmaceuticals Raises $50M

Mountain View-based MAP Pharmaceuticals has riased $50M in its Series D round, the company said today. MAP is developing treatments for respiratory and CNS diseases. Investors in the firm were D.E. Shaw group, and previous investors Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital, Bay City Capital, and Skyline Ventures. More information »